CA2871057A1 - Compositions et procedes pour le traitement de thrombose et la prolongation de la survie de plaquettes stockees - Google Patents

Compositions et procedes pour le traitement de thrombose et la prolongation de la survie de plaquettes stockees Download PDF

Info

Publication number
CA2871057A1
CA2871057A1 CA2871057A CA2871057A CA2871057A1 CA 2871057 A1 CA2871057 A1 CA 2871057A1 CA 2871057 A CA2871057 A CA 2871057A CA 2871057 A CA2871057 A CA 2871057A CA 2871057 A1 CA2871057 A1 CA 2871057A1
Authority
CA
Canada
Prior art keywords
gcpf
platelets
seq
binding
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2871057A
Other languages
English (en)
Inventor
Gray Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasculogics Inc
Original Assignee
Vasculogics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasculogics Inc filed Critical Vasculogics Inc
Publication of CA2871057A1 publication Critical patent/CA2871057A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés et des compositions, comprenant des compositions pharmaceutiques, pour traiter une vaso-occlusion se rapportant à une drépanocytose, une thrombose, une inflammation vasculaire et une thrombocytopénie. Les procédés et compositions de la présente invention sont également utiles pour prolonger la durée de stockage utile de plaquettes, par addition d'une protéine de fusion peptide cyclique de liaison à GPIba (GCPF).
CA2871057A 2011-12-23 2012-12-22 Compositions et procedes pour le traitement de thrombose et la prolongation de la survie de plaquettes stockees Abandoned CA2871057A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580110P 2011-12-23 2011-12-23
US61/580,110 2011-12-23
PCT/US2012/071530 WO2013096932A1 (fr) 2011-12-23 2012-12-22 Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées

Publications (1)

Publication Number Publication Date
CA2871057A1 true CA2871057A1 (fr) 2013-06-27

Family

ID=48669595

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871057A Abandoned CA2871057A1 (fr) 2011-12-23 2012-12-22 Compositions et procedes pour le traitement de thrombose et la prolongation de la survie de plaquettes stockees

Country Status (3)

Country Link
EP (1) EP2794007A4 (fr)
CA (1) CA2871057A1 (fr)
WO (1) WO2013096932A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081678B2 (en) 2013-02-04 2018-09-25 Emory University Specific binding antibodies of glycoprotein IB alpha as selective ectodomain shedding inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035779A1 (es) * 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
WO2004111089A2 (fr) * 2003-06-11 2004-12-23 WYETH A Corporaton of the State of Delaware Polypeptides de fusion de variants de glycoproteines ib-$g(a) de plaquette et leurs methodes
US9266923B2 (en) * 2010-06-24 2016-02-23 Gray D. Shaw Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets
US20130216513A1 (en) * 2010-07-09 2013-08-22 Biogen Idec Hemophilia Inc. Chimeric Clotting Factors

Also Published As

Publication number Publication date
EP2794007A1 (fr) 2014-10-29
EP2794007A4 (fr) 2015-11-18
WO2013096932A1 (fr) 2013-06-27

Similar Documents

Publication Publication Date Title
JP5250548B2 (ja) 疾患の治療のための補体ｈ因子の標的化
US7615533B2 (en) TPO peptide compounds for treatment of anemia
US9266923B2 (en) Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets
EP2785843B1 (fr) Nouveaux antagonistes de sélectine améliorés
US20230203128A1 (en) Methods to Reduce Adverse effects of Activated T Cells
NO341872B1 (no) Anvendelse av TPO-peptidforbindelser og farmasøytiske sammensetninger i behandling av anemi
CA2871057A1 (fr) Compositions et procedes pour le traitement de thrombose et la prolongation de la survie de plaquettes stockees
US20210238238A1 (en) Soluble complement receptor type i variants and uses thereof
US20230303657A1 (en) Fusion Molecules of PSGL-1 or TSGL Anionic Domains to Checkpoint-Modulating Antibodies and Other Antibodies
US11028144B2 (en) Soluble glycoprotein V for treating thrombotic diseases
CN118382640A (zh) 人源化抗cd40抗体的药物组合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161222

FZDE Discontinued

Effective date: 20161222